Literature DB >> 12075699

Update on the management of ovarian cancer.

Robert F Ozols1.   

Abstract

Ovarian cancer remains the leading gynecologic cause of death in the United States and the Western world. Progression to metastatic disease prior to diagnosis contributes to the high mortality rate associated with ovarian cancer. The current article reviews surgical and drug therapies for ovarian cancer. Prognostic factors and preventative treatment are also discussed. Surgery is essential for accurate staging of ovarian cancer and treatment. Cytoreduction, combined with chemotherapy, may relieve symptoms associated with bowel obstruction and improve survival. Management of early-stage ovarian cancer depends upon risk status determined via comprehensive staging at the time of surgical resection. High-risk, but not low-risk, patients require adjuvant chemotherapy. Studies comparing various combinations of cytotoxic agents for the treatment of advanced stage ovarian cancer are described. Despite surgery and chemotherapy, ovarian cancer recurs in approximately 50% of patients. Management of recurrent ovarian cancer and maintenance therapy following remission are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075699

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  23 in total

1.  Salvage therapy with topotecan in heavily pretreated ovarian cancer patients.

Authors:  Lubomir Bodnar; Gabriel Wcislo; Anna Nasilowska; Katarzyna Szarlej-Wcislo; Agnieszka Gasowska-Bodnar; Marta Smoter; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-26       Impact factor: 4.553

2.  High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma.

Authors:  Yingchun Ma; Yubo Ren; Xian Zhang; Li Lin; Yihua Liu; Fengnian Rong; Wenjuan Wen; Fengli Li
Journal:  Virchows Arch       Date:  2014-01-24       Impact factor: 4.064

3.  Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study.

Authors:  D D Correa; J C Root; M Kryza-Lacombe; M Mehta; S Karimi; M L Hensley; N Relkin
Journal:  Brain Imaging Behav       Date:  2017-12       Impact factor: 3.978

4.  Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Authors:  Nathalie Scholler; Barbara Garvik; Martha Hayden-Ledbetter; Toni Kline; Nicole Urban
Journal:  Cancer Lett       Date:  2006-05-04       Impact factor: 8.679

5.  Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Authors:  J-P Delord; S Quideau; P Rochaix; O Caselles; B Couderc; I Hennebelle; F Courbon; P Canal; B C Allal
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

6.  Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.

Authors:  You Wang; Yuchan Wang; Chun Cheng; Yuhong Ji; Yueming Zhao; Lin Zou; Aiguo Shen
Journal:  J Cancer Res Clin Oncol       Date:  2009-01-13       Impact factor: 4.553

7.  High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma.

Authors:  W-F Cheng; C-Y Huang; M-C Chang; Y-H Hu; Y-C Chiang; Y-L Chen; C-Y Hsieh; C-A Chen
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

8.  Ovarian cancer survival population differences: a "high resolution study" comparing Philippine residents, and Filipino-Americans and Caucasians living in the US.

Authors:  Maria Theresa M Redaniel; Adriano Laudico; Maria Rica Mirasol-Lumague; Adam Gondos; Gemma Leonora Uy; Jean Ann Toral; Doris Benavides; Hermann Brenner
Journal:  BMC Cancer       Date:  2009-09-24       Impact factor: 4.430

9.  Mucins in ovarian cancer diagnosis and therapy.

Authors:  Subhash C Chauhan; Deepak Kumar; Meena Jaggi
Journal:  J Ovarian Res       Date:  2009-12-24       Impact factor: 4.234

10.  Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.

Authors:  Emmanuel Guardiola; Delphine Delroeux; Bruno Heyd; Marielle Combe; Veronique Lorgis; Martin Demarchi; Ulrich Stein; Bernard Royer; Bruno Chauffert; Xavier Pivot
Journal:  World J Surg Oncol       Date:  2009-02-09       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.